Weaver Capital Management LLC Buys 17,057 Shares of Danaher Corporation $DHR

Weaver Capital Management LLC raised its stake in Danaher Corporation (NYSE:DHR) by 1,311.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,358 shares of the conglomerate’s stock after acquiring an additional 17,057 shares during the period. Weaver Capital Management LLC’s holdings in Danaher were worth $4,067,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of DHR. Assenagon Asset Management S.A. lifted its position in shares of Danaher by 5,317.4% in the third quarter. Assenagon Asset Management S.A. now owns 2,103,255 shares of the conglomerate’s stock worth $465,976,000 after buying an additional 2,064,431 shares in the last quarter. Retirement Planning Co of New England Inc. bought a new position in Danaher during the third quarter valued at approximately $3,032,000. Mystic Asset Management Inc. purchased a new position in Danaher during the 3rd quarter valued at approximately $4,467,000. RDA Financial Network grew its holdings in Danaher by 166.9% during the 3rd quarter. RDA Financial Network now owns 6,468 shares of the conglomerate’s stock valued at $1,433,000 after buying an additional 4,045 shares in the last quarter. Finally, Ninety One UK Ltd grew its holdings in Danaher by 22.4% during the 3rd quarter. Ninety One UK Ltd now owns 64,880 shares of the conglomerate’s stock valued at $14,374,000 after buying an additional 11,890 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DHR. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. TD Cowen increased their target price on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank Of Canada raised their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Finally, Barclays boosted their price target on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Stock Up 3.0%

Shares of NYSE DHR opened at $231.52 on Friday. The firm’s 50-day moving average price is $213.55 and its 200-day moving average price is $195.74. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.77 EPS. On average, equities research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is 28.42%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.